Medpace
MEDPMEDP · Stock Price
Historical price data
Overview
Medpace is a mission-driven CRO focused on accelerating the global development of safe and effective medical therapeutics through an uncompromising commitment to quality and ethical standards. The company has achieved a $13+ billion valuation through over 30 years of purely organic growth, avoiding the integration challenges of M&A to deliver consistent, high-touch service. Its core strategy revolves around a vertically integrated, full-service model and a 'One Team' approach that embeds therapeutic expertise into client programs, making it the trusted partner for approximately 90% of its clients, which are emerging biotech firms.
Technology Platform
A vertically integrated, full-service CRO platform combining traditional clinical development services with wholly-owned central laboratories, bioanalytical labs, imaging and ECG core labs, a Phase I unit, and a proprietary Clinical Trial Management System (CTMS) for seamless execution.
Pipeline
74| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Lesinurad + XOI + Placebo + colchicine + corticosteroids | Gout | Approved | |
| VI-0521 + VI-0521 + Placebo matched phentermine/topiramate | Obesity | Phase 3 | |
| TNX-103 + Placebo | Pulmonary Hypertension | Phase 3 | |
| lerodalcibep | Heterozygous Familial Hypercholesterolemia | Phase 3 | |
| lerodalcibep | Cardiovascular Disease With Mention of Arteriosclerosis | Phase 3 |
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Medpace competes with large, full-service CROs (e.g., IQVIA, ICON) and specialist firms. Its differentiation stems from a unique, organically-grown vertically integrated model, a deep strategic focus on biotech clients, and a 'One Team' approach that ensures therapeutic expertise and continuity, allowing it to command a premium position in its core market.
